Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8943994 | 0.83 | — | — | |
| SCHEMBL11193512 | 0.80 | TSHR (0.46) | TSHRLMNASMN1; SMN2TDP1NOS3 | |
| SCHEMBL223886 | 0.80 | TSHR (0.46) | TSHRLMNASMN1; SMN2TDP1NOS3 | |
| Ammonia Solution, Strong SCHEMBL28130901 | 0.76 | TSHR (0.43) | TSHRLMNASMN1; SMN2TDP1NOS3 | |
| SCHEMBL28776185 | 0.76 | TSHR (0.43) | TSHRLMNASMN1; SMN2TDP1NOS3 | |
| Water SCHEMBL28084836 | 0.76 | TSHR (0.43) | TSHRLMNASMN1; SMN2TDP1NOS3 | |
| SCHEMBL10941694 | 0.76 | TSHR (0.43) | TSHRLMNASMN1; SMN2TDP1NOS3 | |
| SCHEMBL3476016 | 0.76 | TSHR (0.43) | TSHRLMNASMN1; SMN2TDP1NOS3 | |
| SCHEMBL10947396 | 0.76 | TSHR (0.43) | TSHRLMNAGMNNMAPTSMN1; SMN2 | |
| SCHEMBL28275329 | 0.76 | TSHR (0.43) | TSHRLMNASMN1; SMN2TDP1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2578598-B1 | Componds derived from normuramyldipeptide | IMUTHES LTD (GB) | 2015-04-15 | — | — | EP | disclosed |
| US-8653049-B2 | Normuramyl glycopeptide compounds | IMUTHES LIMITED (GB) | 2014-02-18 | — | — | US | disclosed |
| EP-2578598-A1 | Componds derived from normuramyldipeptide | IMUTHES LIMITED (GB) | 2013-04-10 | — | — | EP | disclosed |
| EP-2271661-A2 | COMPOUNDS DERIVED FROM MURAMYLDIPEPTIDE | IMUTHES LIMITED (GB) | 2011-01-12 | — | — | EP | disclosed |
| US-20110002983-A1 | COMPOUND | IMUTHES LIMITED (GB) | 2011-01-06 | — | — | US | disclosed |
| WO-2009115782-A2 | COMPOUND | IMUTHES LIMITED (GB) | 2009-09-24 | — | — | WO | disclosed |
| EP-0376747-B1 | Methacrylimide-containing polymer and resin composition containing said polymer | MITSUBISHI RAYON CO (JP) | 1995-02-08 | — | — | EP | disclosed |
| EP-0376747-A2 | Methacrylimide-containing polymer and resin composition containing said polymer | MITSUBISHI RAYON CO., LTD. (JP) | 1990-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110002983-A1 | COMPOUND | C5AR1, C5AR2, ARG1 | TSHR 1496/4885CYP3A4 2931/4885CYP2D6 2714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.